{
    "clinical_study": {
        "@rank": "35381", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe to give L-743,872 to men with candidal\n      esophagitis, an AIDS-related yeast infection in the esophagus."
        }, 
        "brief_title": "A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis", 
        "condition": [
            "Candidiasis, Esophageal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis", 
                "Esophagitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of\n      three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the\n      final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are an 18- to 65-year-old man with candidal esophagitis."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "June 19, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005921", 
            "org_study_id": "267A", 
            "secondary_id": "007-00"
        }, 
        "intervention": {
            "intervention_name": "L-743,872", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Caspofungin"
        }, 
        "keyword": [
            "Dose-Response Relationship, Drug", 
            "Antifungal Agents", 
            "Candidiasis", 
            "Esophageal Diseases", 
            "MK 0991"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rahway", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07065"
                }, 
                "name": "Gary Calandra"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005921"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {
        "Gary Calandra": "40.608 -74.278"
    }
}